Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results
Date:9/17/2009

he process of arranging their EU trial program, including an initial Phase I and several different Phase II's.
  • PCI-34051, Pharmacyclics' HDAC 8 Inhibitor, is currently in preclinical studies, and is planned to be developed as a unique treatment modality for autoimmune disorders. The company is anticipating further results and to conclude its preclinical work by calendar year 2010.
  • PCI-0120, Motexafin Gadelinium (MGd) is currently tested in two NCI sponsored Phase II studies. Both have extended survival as their endpoint and both completed the patient enrollment. The aggregation of the study results are dependent upon the NCI. For its pediatric pontine glioma trial Pharmacyclics is expecting results in the first half of calendar 2010. The other Phase II study in which MGd was tested in patients with newly diagnosed glioblastoma in combination with temazolamide and radiation, Pharmacyclics is expecting survival results in calendar 2011.
  • PCI-27483, a potent small molecule inhibitor of coagulation Factor VIIa, is projected to begin a multicenter Phase I/II study before the end of calendar 2009 in patients with locally advanced pancreatic cancer with gemcitabine therapy. The company has recently received FDA clearance to move ahead with this trial.
  • PCI-32765, the company's BTK inhibitor, is currently in a Phase I trial in patients with relapsed or refractory surface immunoglobulin positive B-cell Non-Hodgkin's Lymphoma (including SLL/CLL). The trial design allows for six dosing cohorts. The enrollment is anticipated to be completed during Q2 of calendar 2010, with full trial results expected in the second half of calendar 2010. At this time, the Company does not believe that all six dosing cohorts will be necessary to conclude this Phase I study.
  • An IND has been filed in August for PCI-32765 with the Allergy and Immunology Division, to allow Pharmacyclics to start a healthy volunteers study in patie
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine news :

    1. Pharmacyclics Sets Record Date for Rights Offering
    2. Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
    3. Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer
    4. Pharmacyclics Receives Nasdaq Notification
    5. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
    6. Pharmacyclics Reports Third Quarter 2008 Financial Results
    7. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
    8. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
    9. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
    10. J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance
    11. Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2015)... DC (PRWEB) May 05, 2015 “Given that ... the findings in the CDC report are a major step ... rethink health for everyone. For the past 30 years, data ... the standard model. Today we see the urgency and the ... achieve the best health outcomes for all,” said Jane L. ...
    (Date:5/5/2015)... The global lab automation market is expected ... in 2014, at an estimated CAGR of 6.7% from ... market on the basis of equipment and software, application, ... basis of application, Lab Automation Market is classified into ... Drug discovery is a major application of the lab ...
    (Date:5/5/2015)... The newly minted Regan Arts has just released a unique self-help ... from his 20 years working in the field of wilderness therapy. ... a parenting book and why this one, she replied, “What resonates ... it is a journey, not a destination...that the question is not ... together and sometimes not...that each of our struggles is unique. What ...
    (Date:5/5/2015)... Georgia (PRWEB) May 05, 2015 ... of Victoria BC announced the Skedans Sensor Collaboration ... platform, for mobile and web app developers, provides tooling ... airborne and mobile sensors. , The Skedans Sensor Collaboration ... the intersection of the Internet of Things, Web Real ...
    (Date:5/5/2015)... 2015 Information Innovators Inc. ... the federal government, today announced its acquisition of ... provides solutions exclusively to federal government customers through ... cyber security, health services, and program management support. ... credentials as a Third Party Assessment Organization (3PAO) ...
    Breaking Medicine News(10 mins):Health News:“Its about time,” Declares the National Alliance for Hispanic Health on First CDC Study of Hispanic Health 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4
    ... Serena Gordon HealthDay Reporter , FRIDAY, March 25 (HealthDay ... health today, but five years ago his body was wasting away. ... know what. That something was type 1 diabetes, and ... his life, he,s healthy now because he spends a lot of ...
    ... 2011 The U.S. Food and Drug Administration (FDA) announced ... the deadliest and most difficult-to-treat form of skin cancer. The ... of any kind ever shown in a large, randomized phase ... patients with metastatic melanoma who no longer respond to standard ...
    ... CHAPEL HILL, N.C. The American Association for Cancer ... professor of medicine and a member of UNC Lineberger ... Foundation-AACR Grant for Translational Breast Cancer Research. The ... Annual Meeting, to be held in Orlando, Florida, April ...
    ... , FRIDAY, March 25 (HealthDay News) -- Researchers have ... live in the intestine, leading to immune system problems. ... said the team at Ohio State University. The communities of ... potentially harmful bacteria. The study is published in the ...
    ... in French . , It sounds unbelievably ... for asthma treatment, attached to the drug prescription, improves ... often signal a management failure," said Dr. Francine Ducharme, ... the Sainte-Justine University Hospital Centre. "This research shows that, ...
    ... any given time tens of thousands of these neurons might be ... trying to be heard by his friend across a crowded room, ... heard above the din. Researchers from the Center for ... University and the University of Pittsburgh, have found two ways that ...
    Cached Medicine News:Health News:Nick Jonas Lives Large, Despite Diabetes 2Health News:Nick Jonas Lives Large, Despite Diabetes 3Health News:FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma 2Health News:FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma 3Health News:FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma 4Health News:UNC physician-scientist receives grant to study breast cancer brain metastases 2Health News:Young asthmatics are leaving emergency rooms missing critical documentation 2Health News:'Can you hear me now?' Researchers detail how neurons decide how to transmit information 2
    (Date:5/5/2015)... 5, 2015 /CNW Telbec/ - Ergoresearch Ltd ... and known under the « Équilibre, orthèses ... the transaction previously announced on April 23, 2015 regarding ...  shares of Orthoconcept (2008) inc.   The ... shares (TSXV: ERG) to the vending shareholder, namely 9211-5096 ...
    (Date:5/5/2015)... 5, 2015  The preclinical contract research organization ... of drugs and safety testing of medical devices, announces ... Preclinical Studies, presented at this week,s annual meeting of ... in Denver, CO. The title ... a Novel, Cross-Linked, Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) Polymer ...
    (Date:5/5/2015)... ST. LOUIS and NIJMEGEN, ... -- EndoStim, a medical device company developing lower ... disease (GERD) announced long-term, 3-year, positive safety and ... of reflux symptoms of both heartburn and regurgitation ... 24-hour esophageal pH test) with near-complete elimination of ...
    Breaking Medicine Technology:Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: